{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034898","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.310866+00:00","generated_at":"2026-05-30T00:50:50.052611+00:00","sec_items":["2.02","5.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO","bullets":["Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.","Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.","ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.","CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.","Board separated Chairman/CEO roles; John Donofrio appointed Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034898","json":"https://secwatch.observer/filing/0001437749-24-034898.json","markdown":"https://secwatch.observer/filing/0001437749-24-034898.md","text":"https://secwatch.observer/filing/0001437749-24-034898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/aytu20240909_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:50:50.052611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08781d05b7","claim":"Ryan Selhorn was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On November 11, 2024, the board of directors of the Company (the \" Board \") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer, Corporate Secretary and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"b52154d0ce","claim":"Mark K. Oki was terminated as Chief Financial Officer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}